3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
3
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Metastatic Urothelial Cancer
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
selpercatinib
2
larotrectinib
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
repotrectinib
1
relatlimab
1
pralsetinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
cabozantinib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Sunitinib
1
Specimen Handling
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has announcements
×
Thyroid Neoplasms
×
sacituzumab govitecan
×
Clear all
No trials found.